WilmerHale Counsels Agios Pharmaceuticals in Exclusive License Agreement with Aurigene Discovery Technologies

WilmerHale Counsels Agios Pharmaceuticals in Exclusive License Agreement with Aurigene Discovery Technologies

Firm News

Agios Pharmaceuticals, Inc. and Aurigene Discovery Technologies Limited announced a global license agreement to research, develop and commercialize small molecule inhibitors of an undisclosed cancer metabolism target. Under the terms of the agreement, Agios will conduct pre-clinical studies and, if successful, fund further global research and development, as well as regulatory and commercial activities.

The WilmerHale team counseling Agios Pharmaceuticals included Steven Barrett and Mat Trachok.

Read Agios Pharmaceuticals' press release for more information.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.